Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Mesenchymal Stem Cell Secretome Attenuates PrP 106-126 -Induced Neurotoxicity by Suppressing Neuroinflammation and Apoptosis and Enhances Cell Migration.

Zayed M., Jeong BH.

Animal Study on Neuroinflammation, Chronic Inflammation, published in Cells (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Cells (2025)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
40498027
PMCID
PMC12154356
DOI
10.3390/cells14110851
Citations
2

Abstract (original English)

Prion diseases are disorders caused by the misfolding of prion protein (PrP Sc ), leading to the accumulation of an abnormal form of the normal prion protein (PrP) found in the host. The secretome of mesenchymal stem cells (MSCs), including paracrine-soluble factors, holds promising potential to stimulate host regenerative capability and alleviate organ disorders. In this research, our goal was to investigate the neuroprotective properties of the secretome derived from adipose-derived mesenchymal stem cells (AdMSC secretome) in relation to the toxicity caused by PrP 106-126 in SH-SY5Y cells. The findings showed that PrP 106-126 treatment exacerbated the neurotoxicity of SH-SY5Y cells, as indicated by increased lactate dehydrogenase (LDH) release. However, the AdMSC secretome significantly decreased LDH release. Under PrP 106-126 stimulation, the AdMSC secretome downregulated inflammatory markers ( TNF-α and IL-1β ) and upregulated anti-inflammatory IL-10 . Treatment with the AdMSC secretome markedly reduced GFAP immunoreactivity in astrocytic C8D1A cells compared to treatment with PrP 106-126 alone. In addition, the AdMSC secretome reduced Iba-1 immunoreactivity in BV2 cells activated by LPS. Western blot analysis showed that the AdMSC secretome inhibited pro-apoptotic factor Bax induced by PrP 106-126 and increased the expression of anti-apoptotic factor Bcl-2. However, no sig

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Mesenchymal Stem CellsApoptosisHumansCell MovementSecretomePeptide FragmentsNeuroinflammatory DiseasesCell Line, TumorAnimalsMice

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research